OA
REGN icon

Operose Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Operose Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$773 – 644
2026
Q1 		$773 Buy
+1
New +$766 ﹤0.01% 554
2025
Q1 		– Sell
-5
Closed -$3.56K – 441
2024
Q4 		$3.56K Buy
+5
New +$4.2K ﹤0.01% 376

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Operose Advisors's REGN Position: Q2 2026 in Review

Operose Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 1 share — an estimated $773 sold.

Operose Advisors first reported a position in REGN in Q4 2024 and held it in 2 quarters. The position peaked at $3.56K in Q4 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Operose Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Operose Advisors sold 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $773.
  • Operose Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Operose Advisors's Regeneron Pharmaceuticals position peaked at $3.56K in Q4 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.